Dunwan Zhu

Dunwan Zhu

Auto-generated profile, based on publicly available information

Dunwan Zhu

State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in Nano Letters
Verified
Journal Article
Closed access
LZLinhua Zhang
Linhua Zhang
SWShengjie Wu
Shengjie Wu
YQYu Qin
Yu Qin
FFFan Fan
Fan Fan
ZZZhiming Zhang
Zhiming Zhang
DZDunwan Zhu
Dunwan Zhu

23 August 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
CWChaoxiong Wu
Chaoxiong Wu
QYQingyu Yu
Qingyu Yu
CHChenlu Huang
Chenlu Huang
FLFangzhou Li
Fangzhou Li
LZLinhua Zhang
Linhua Zhang
DZDunwan Zhu
Dunwan Zhu
Microneedles (MNs) serve as a revolutionary paradigm in transdermal drug delivery, heralding a viable resolution to the formidable barriers presented by the cutaneous interface. This review examines MNs as an advanced approach to enhancing dermatological pathology management. It explores the complex dermis structure and highlights the limitations of traditional transdermal methods, emphasizing MNs' advantage in bypassing the stratum corneum to deliver drugs directly to the subdermal matrix. The discourse outlines the diverse typologies of MNs, including solid, coated, hollow, hydrogel, and dissolvable versions. Each type is characterized by its unique applications and benefits. The treatise details the deployment of MNs in the alleviation of cutaneous cancers, the administration of inflammatory dermatoses such as psoriasis and atopic dermatitis, and their utility in wound management. Additionally, the paper contemplates the prospects of MNs within the realm of aesthetic dermatology and the burgeoning market traction of cosmetic MN formulations. The review summarizes the scientific and commercial challenges to the clinical adoption of MN therapeutics, including dosage calibration, pharmacodynamics, biocompatibility, patient compliance, sterilization, mass production, and regulatory oversight. It emphasizes the need for ongoing research, innovation, and regulatory harmonization to overcome these obstacles and fully realize MNs’ potential in treating skin diseases and improving patient welfare.

24 February 2023 in Journal of Controlled Release
Verified
Journal Article
Closed access
YYYunfei Yi
Yunfei Yi
MYMian Yu
Mian Yu
WLWen Li
Wen Li
DZDunwan Zhu
Dunwan Zhu
Lin MeiLin Mei
Lin Mei
Meitong OuMeitong Ou
Meitong Ou

2 June 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
QLQianqian Li
Qianqian Li
ZSZhaoqing Shi
Zhaoqing Shi
FZFan Zhang
Fan Zhang
WZWeiwei Zeng
Weiwei Zeng
DZDunwan Zhu
Dunwan Zhu
Lin MeiLin Mei
Lin Mei
The immune system is involved in the initiation and progression of cancer. Research on cancer and immunity has contributed to the development of several clinically successful immunotherapies. These immunotherapies often act on a single step of the cancer–immunity cycle. In recent years, the discovery of new nanomaterials has dramatically expanded the functions and potential applications of nanomaterials. In addition to acting as drug-delivery platforms, some nanomaterials can induce the immunogenic cell death (ICD) of cancer cells or regulate the profile and strength of the immune response as immunomodulators. Based on their versatility, nanomaterials may serve as an integrated platform for multiple drugs or therapeutic strategies, simultaneously targeting several steps of the cancer–immunity cycle to enhance the outcome of anticancer immune response. To illustrate the critical roles of nanomaterials in cancer immunotherapies based on cancer–immunity cycle, this review will comprehensively describe the crosstalk between the immune system and cancer, and the current applications of nanomaterials, including drug carriers, ICD inducers, and immunomodulators. Moreover, this review will provide a detailed discussion of the knowledge regarding developing combinational cancer immunotherapies based on the cancer–immunity cycle, hoping to maximize the efficacy of these treatments assisted by nanomaterials.

24 February 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
CHChenlu Huang
Chenlu Huang
LZLi Zhang
Li Zhang
QGQing Guo
Qing Guo
YZYueyue Zuo
Yueyue Zuo
NWNannan Wang
Nannan Wang
LZLinhua Zhang
Linhua Zhang

20 February 2018 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
YPYunmei Peng
Yunmei Peng
JNJunpeng Nie
Junpeng Nie
WCWei Cheng
Wei Cheng
GLGan Liu
Gan Liu
DZDunwan Zhu
Dunwan Zhu
Xiaowei ZengXiaowei Zeng
Xiaowei Zeng
The integration of various therapy strategies into a single nanoplatform for synergistic cancer treatment has presented a great prospect. Herein, docetaxel (DTX)-loaded poly lactic-co-glycolic acid (PLGA)-coated polydopamine modified with D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) was synthesized for chemo-photothermal synergistic therapy against cancer. Firstly, the DTX-loaded PLGA NPs were prepared by a facile and robust nanoprecipitation method. Then, they were coated with dopamine to achieve the photothermal effects and to be further modified with TPGS, which can inhibit the P-glycoprotein-mediated multidrug resistance (MDR). The near-infrared (NIR) laser irradiation triggered DTX release from DTX-loaded PLGA NPs@PDA-TPGS, and then the chemo-photothermal therapy effect could be enhanced. The in vitro experimental results illustrated that DTX-loaded PLGA NPs@PDA-TPGS exhibits excellent photothermal conservation properties and remarkable cell-killing efficiency. In vivo antitumor studies further confirmed that DTX-loaded PLGA NPs@PDA-TPGS could present an outstanding synergistic antitumor efficacy compared with any monotherapy. This work exhibits a novel nanoplatform, which could not only load chemotherapy drugs efficiently, but could also improve the therapeutic effect of chemotherapy drugs by overcoming MDR and light-mediated photothermal cancer therapy.